Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read ...
News from the week beginning 3rd November includes items from @1111Systems, @CybageSoftware, @Deltek, @Expereo, @Epicor, @Ultimo, @Percona, @Planful, @Quantexa and @Quantware ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback